Gilead and Galapagos NV announce safety data for filgotinib in RA
Category: #healthcare  By Mateen Dalal  Date: 2019-11-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gilead and Galapagos NV announce safety data for filgotinib in RA
  • The companies unveiled safety and efficacy results for filgotinib in numerous RA patients
     
  • This data will be presented at the annual 2019 ACR/ARP meeting in Atlanta

Gilead Sciences, an American biopharmaceutical firm and Galapagos NV, a European pharmaceutical research company, has recently announced complete results of the clinical research program that evaluated filgotinib, an oral, investigational and selective JAK1 inhibitor in adults with rheumatoid arthritis (RA) activity ranging from moderate to severe.

The data reveal a durable safety and efficacy result with filgotinib in numerous patients suffering from RA, both the MTX-naïve patients as well as the ones who’ve had an insufficient response to two or more disease-modifying antirheumatic drugs (bDMARDS). The analysis is expected to be introduced at the 2019 ACR/ARP Annual Meeting (American College of Rheumatology/Association of Rheumatology Professionals) in Atlanta, US.

Senior vice president for Inflammation and Respiratory Diseases at Gilead Sciences, John Sundy, MD, PhD, stated that the new evaluation is consistently demonstrating safety and efficacy profile of filgotinib for a large number of patients, that also includes those patients who have used other treatments but need other tolerable and effective options.

Sundy further commented that the company is now one step closer to deliver filgotinib for all patients, with the presenting of the results at the ACR.

Chief Medical Officer at Galapagos, Dr. Walid Abi-Saab said that people who are suffering from RA often tend to struggle with devastating, long-term symptoms that have the capability of negatively impacting the quality of their lives. Saab added that the latest evaluation continues to back the clinical potential of filgotinib in patients suffering from RA and the patients whose disease may not have been sufficiently under control by ongoing treatments.

Filgotinib happens to be an investigational agent that has not received approval by the European Medicines Agency, U.S. Food and Drug Administration, or other regulatory bodies yet.

 

Source Credit- https://www.gilead.com/news-and-press/press-room/press-releases/2019/11/new-data-on-filgotinib-in-rheumatoid-arthritis-ra-demonstrate-durable-efficacy-and-safety-profile

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Advaxis reveals positive data from Phase 1/2 ADXS-503 trial for NSCLC
Advaxis reveals positive data from Phase 1/2 ADXS-503 trial for NSCLC
By Mateen Dalal

Advaxis, Inc., a clinical-stage biotechnology company developing and commercializing immunotherapy p...

Mustang Bio observes complete response for MB-106 in lymphoma patient
Mustang Bio observes complete response for MB-106 in lymphoma patient
By Mateen Dalal

  MB-106 has been developed for cancer in partnership with Fred Hutchinson Cancer Research C...

FDA approves three drugs for counter use through Rx-to-OTC process
FDA approves three drugs for counter use through Rx-to-OTC process
By Mateen Dalal

The U.S. FDA (Food and Drug Administration) has reportedly approved three drugs as an over-the-count...